| Serious cardiovascular adverse events reported with intravenous sedatives: a retrospective analysis of the MedWatch adverse event reporting system MS Duprey, NS Al-Qadheeb, N O’Donnell, KB Hoffman, J Weinstock, ... Drugs-real world outcomes 6, 141-149, 2019 | 8 | 2019 |
| Amyotrophic lateral sclerosis associated with statin use: a disproportionality analysis of the FDA’s adverse event reporting system BA Golomb, A Verden, AK Messner, HJ Koslik, KB Hoffman Drug Safety 41, 403-413, 2018 | 37 | 2018 |
| Analysis of spontaneous postmarket case reports submitted to the FDA regarding thromboembolic adverse events and JAK inhibitors A Verden, M Dimbil, R Kyle, B Overstreet, KB Hoffman Drug safety 41 (4), 357-361, 2018 | 143 | 2018 |
| Compositions and methods for enhancing the effectiveness of systemic, HIPEC, IP, and related cancer treatments G Keeling, KB Hoffman US Patent 9,669,053, 2017 | 2 | 2017 |
| Compositions and Methods for Enhancing the Effectiveness of Systemic, HIPEC, IP, and Related Cancer Treatments G Keeling, KB Hoffman US Patent 20170232037A1, 2017 | 1 | 2017 |
| ADVERSE EVENT DATA AS PROXY TO DETERMINE TOTAL MEDICAL COSTS FOR TNF-ALPHA INHIBITORS KB Hoffman, M Dimbil, T Bartholow, A Lukazewski, J Davis VALUE IN HEALTH 20 (5), A145-A145, 2017 | | 2017 |
| I41 Post-marketing adverse events (AES) associated with tetrabenazine (TBZ): findings using FDA’s adverse event reporting system (FAERS) DO Claassen, R Iyer, M Dimbil, A Giron, L De Boer, S Gandhi, ... Journal of Neurology, Neurosurgery & Psychiatry 87 (Suppl 1), A73-A73, 2016 | | 2016 |
| A pharmacovigilance signaling system based on FDA regulatory action and post-marketing adverse event reports KB Hoffman, M Dimbil, NP Tatonetti, RF Kyle Drug safety 39, 561-575, 2016 | 31 | 2016 |
| HEPATITIS C MEDICATIONS: ESTIMATING THE COSTS OF ADVERSE DRUG REACTIONS AND POOR PATIENT OUTCOMES KB Hoffman, A Giron, M Dimbil Value in Health 19 (3), A216, 2016 | | 2016 |
| A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes KB Hoffman, M Dimbil, RF Kyle, NP Tatonetti, CB Erdman, A Demakas, ... Journal of managed care & specialty pharmacy 21 (12), 1134-1143c, 2015 | 10 | 2015 |
| System and Method for Surveillance and Evaluation of Safety Risks Associated with Medical Interventions KB Hoffman, BM Overstreet, CB Erdman, R Kyle US Patent App. 14/752,452, 2015 | 2 | 2015 |
| Calculating the costs of adverse Drug Reactions From Post-Marketing Data: Implications for outcomes Research KB Hoffman, M Dimbil Value in Health 18 (3), A281, 2015 | | 2015 |
| Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS) KB Hoffman, AR Demakas, M Dimbil, NP Tatonetti, CB Erdman Drug safety 37, 971-980, 2014 | 83 | 2014 |
| System and method for surveillance and evaluation of safety risks associated with medical interventions KB Hoffman, BM Overstreet, CB Erdman, R Kyle US Patent 20140358576A1, 2014 | 7 | 2014 |
| The Weber effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010 KB Hoffman, M Dimbil, CB Erdman, NP Tatonetti, BM Overstreet Drug safety 37, 283-294, 2014 | 161 | 2014 |
| Post-approval adverse events of new and old anticoagulants KB Hoffman, A Demakas, CB Erdman, M Dimbil BMJ 348, g1859, 2014 | 3 | 2014 |
| Oseltamivir: postmarket neuropsychiatric data from FAERS KB Hoffman Reactions 1463, 3-3, 2013 | | 2013 |
| Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012 KB Hoffman, A Demakas, CB Erdman, M Dimbil, PM Doraiswamy Bmj 347, 2013 | 39 | 2013 |
| Development of a drug safety ePlatform for physicians, pharmacists, and consumers based on post-marketing adverse events KB Hoffman, BM Overstreet, PM Doraiswamy Drugs and Therapy Studies 3 (1), e4-e4, 2013 | 17 | 2013 |
| Tamiflu correspondence with Roche KB Hoffman, A Demakas, CB Erdman, M Dimbil, P Murali | | 2013 |
